Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001011770 | SCV001172130 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2021-06-15 | criteria provided, single submitter | clinical testing | The c.1473+1G>A intronic variant results from a G to A substitution one nucleotide after coding exon 10 of the BMPR1A gene. This alteration occurs at the 3' terminus of the BMPR1A gene, is not expected to trigger nonsense-mediated mRNA decay, and only impacts the last 11% of the protein. The exact functional effect of this alteration is unknown; however, a significant portion of the protein is affected (Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |